-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Calcitonin is a calcitonin derived from neutral granulocytes and macrophages, whose expression is tissue or cell-specific and can be used as a marker of acute inflammatory cell activation.
it can be found in plasma and feces.
The 2005 British Gastroenterology School year will use calcitonin as a new noninvasive diagnostic indicator, wherein fecal calcitonin can be used to distinguish inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) and irritability syndrome (IBS), so its role in monitoring inflammatory inflammatory activities of inflammatory bowel disease is becoming increasingly important.
, fecal calcitonin screening can be used to evaluate endoscopic recurrence in patients after CD surgery, and the effect is significantly better than C-reactive protein.
study was conducted to assess the relationship between continuous fecal calcitonin (Fcal) levels and recurrence under the CD endoscopy in the first three months after surgery.
DOI: In this trial, the researchers randomly controlled the included patients, and randomly divided CD patients who underwent surgery into receiving 2.5 mg / kg / day of thiopental combined oral curcumin (3 g / day) treatment or receiving placebo therapy.
measured Fcad levels one month after surgery (M1) and 3 months after surgery (M3).
endoscopic recurrence (POR) 6 months after surgery is defined as the Rutgerts index of i2b.
48 patients included in the study, there was no significant difference in the mid-Fca level at baseline (p ???0.15), M1 (p???0.44) and M3 (p?0.28).
patients with or without a POR at the time of M6, there was a significant difference in fecal dynamics in the three months after surgery (p.021).
change between the baseline Fcadal level and the M3 level in patients with POR under the endoscopy was significantly higher than in patients who did not relapse (p???0.01).
FcalM3-M0; 10% showed the best performance of the predicted M6 endoscopic POR (AUC - 0.73, sensitivity - 64.7% ( 41.1-82.7) , specificity - 87.5% ( 68) .0-96.3, negative predictions of 77.8% (57.5-91.4) and positive predictions of 78.6% (49.2-95.3).
Figure: High levels of poop calcitonin in CD patients with recurrence under the endoscopy The faeces changes in the first three months after surgery in CD patients with colorectal excision are promising predictor indicators of early endoscopic POR in CD patients.
.